Neogenomics (NEO) Free Cash Flow (2010 - 2026)

Neogenomics has reported Free Cash Flow for 17 years, with the latest figure at -$13.1 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow rose 55.96% year-over-year to -$13.1 million; the trailing twelve-month figure through Mar 2026 stood at $20.2 million (up 162.96% YoY), and the FY2025 full-year result was $3.5 million, down 41.51% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$13.1 million, down from $18.8 million in the prior quarter.
• The five-year high for Free Cash Flow was $38.2 million in Q4 2024, with the low at -$37.3 million in Q1 2022.
• Historically, Free Cash Flow has averaged -$4.3 million across 5 years, with a median of -$1.6 million in 2024.
• Annual changes were most pronounced in 2022 — Free Cash Flow plunged 28982.95% — and 2025, when it surged 1620.76%.
• Neogenomics' Free Cash Flow stood at $21.0 million in 2022, then dropped by 15.13% to $17.8 million in 2023, then surged by 114.77% to $38.2 million in 2024, then tumbled by 50.94% to $18.8 million in 2025, then tumbled by 170.0% to -$13.1 million in 2026.
• The last three Free Cash Flow figures came in at -$13.1 million (Q1 2026), $18.8 million (Q4 2025), and $570000.0 (Q3 2025), per Business Quant data.